Baidu
map

能帮外科医生区分健康或癌变组织的「激光笔」

2015-07-03 shixinxin 煎蛋网

外科医生们用“果冻里取蜘蛛”来形容复杂的脑部肿瘤移除手术。若肿瘤的取出范围太小,癌变细胞的“余党”还会继续作恶——范围太大就会存在误切健康组织,致病人变残疾的风险。 如今英国一家医院正在试用一种像倒车雷达的激光笔,它会在手术刀接近癌变组织边缘的时候发出“哔哔”声,让外科医生清楚误差限度。 英国伦敦帝国学院医疗卫生NHS信托机构的神经外科医生们率先在这一领域使用这种名为Core、像钢笔一样的装置

外科医生们用“果冻里取蜘蛛”来形容复杂的脑部肿瘤移除手术。若肿瘤的取出范围太小,癌变细胞的“余党”还会继续作恶——范围太大就会存在误切健康组织,致病人变残疾的风险。

如今英国一家医院正在试用一种像倒车雷达的激光笔,它会在手术刀接近癌变组织边缘的时候发出“哔哔”声,让外科医生清楚误差限度。

英国伦敦帝国学院医疗卫生NHS信托机构的神经外科医生们率先在这一领域使用这种名为Core、像钢笔一样的装置。该装置会发出近红外线光使肿瘤发亮、扫描鉴别出健康组织和癌变组织的微小差别。

能帮外科医生区分健康或癌变组织的「激光笔」

判断可以在一秒钟内完成。当医生的手术刀靠近健康组织,它会马上发出警告声。在英国,每年约有16,000人被确诊患有脑瘤,与其他癌症相比,死于该疾病的患者多为儿童和40岁以下的成年人。该病类型可以被细分为120多种。外科医生们希望借助Core、这一在加拿大皮肤癌手术中已被证明成功有效的装置,能够帮助他们尽可能多地移除癌变组织,同时缩短手术时间。

上周,帝国医院一个脑部手术中这种探针装置被初次使用,假如效果理想的话,在接下来的一年时间里,该装置会应用在30多位患者的手术中。

推进这个项目把Core介绍到英国的高级神经外科实习生Babar Vaqas说:“这是前所未有的时刻。脑部手术非常复杂,一微米的失误都可能引发重大伤害,造成瘫痪或语言功能问题。拥有能让手术更安全更精确的手段才是真正的胜利。”脑部手术面临的困境是,甚至在显微镜下,大脑的癌变组织和正常组织都很难进行区别。外科医生必须依赖对几份微小的组织切片的化验结果来确认他们移除的是否为癌变组织。组织取样化验、等待结果反馈这一过程需耗时90分钟,而此时患者仍然躺在手术室内。

能帮外科医生区分健康或癌变组织的「激光笔」
外科医生们认为这种像钢笔一样的探针可以为一般长达3小时的手术时间节约30分钟(模特摆拍)

有了这个装置以后,不用再进行实物取样。医生手拿Core靠近手术区域,探针顶部会发出光束,扫描探寻脑部组织化学成分的变化。光照下,因肿瘤的分子振动不同于健康的组织,所以两者反射的光就会截然不同。探针捕捉到这一差别,把信号传给计算机,随即能够读取出该组织是否为癌变组织。Vaqas先生认为这一装置至少为平均时长为3小时的手术时间缩短了半小时。他说:“不到一秒钟的时间,这个装置就能够区别出健康组织和癌变组织。这还意味着我们可以尽量避免不必要的活体组织检查,使手术效率更高。”

Core装置制造商, 为加拿大的Verisante技术公司。他们希望帝国医院的手术能够复制多温华一医院的成功。他们用它检测出1,000名皮肤癌患者。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1279648, encodeId=b1be12e964853, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420635, encodeId=1f93142063509, content=<a href='/topic/show?id=d2514292149' target=_blank style='color:#2F92EE;'>#外科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42921, encryptionId=d2514292149, topicName=外科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a73606138, createdName=ysjykql, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557031, encodeId=facf155e0310b, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30492, encodeId=1b723049211, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:50:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30358, encodeId=1c3030358db, content=好先进, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-05 oliver169
  2. [GetPortalCommentsPageByObjectIdResponse(id=1279648, encodeId=b1be12e964853, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420635, encodeId=1f93142063509, content=<a href='/topic/show?id=d2514292149' target=_blank style='color:#2F92EE;'>#外科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42921, encryptionId=d2514292149, topicName=外科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a73606138, createdName=ysjykql, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557031, encodeId=facf155e0310b, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30492, encodeId=1b723049211, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:50:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30358, encodeId=1c3030358db, content=好先进, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1279648, encodeId=b1be12e964853, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420635, encodeId=1f93142063509, content=<a href='/topic/show?id=d2514292149' target=_blank style='color:#2F92EE;'>#外科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42921, encryptionId=d2514292149, topicName=外科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a73606138, createdName=ysjykql, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557031, encodeId=facf155e0310b, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30492, encodeId=1b723049211, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:50:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30358, encodeId=1c3030358db, content=好先进, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-05 axin014
  4. [GetPortalCommentsPageByObjectIdResponse(id=1279648, encodeId=b1be12e964853, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420635, encodeId=1f93142063509, content=<a href='/topic/show?id=d2514292149' target=_blank style='color:#2F92EE;'>#外科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42921, encryptionId=d2514292149, topicName=外科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a73606138, createdName=ysjykql, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557031, encodeId=facf155e0310b, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30492, encodeId=1b723049211, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:50:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30358, encodeId=1c3030358db, content=好先进, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1279648, encodeId=b1be12e964853, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420635, encodeId=1f93142063509, content=<a href='/topic/show?id=d2514292149' target=_blank style='color:#2F92EE;'>#外科医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42921, encryptionId=d2514292149, topicName=外科医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a73606138, createdName=ysjykql, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557031, encodeId=facf155e0310b, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Sun Jul 05 04:08:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30492, encodeId=1b723049211, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:50:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30358, encodeId=1c3030358db, content=好先进, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Fri Jul 03 23:23:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-03 caierhong

    好先进

    0

相关资讯

中国科大发现克服肿瘤多药耐药新方法

6月26日,国际学术期刊《德国应用化学》在线发表了中国科学技术大学化学与材料科学学院教授梁高林课题组与生命科学学院教授张华凤课题组的合作研究成果,文章标题为Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multi-Drug Resis

免疫肿瘤药物概述与发展

肿瘤免疫治疗是当今全球药物研发领域最大的热门,主要分为三大领域,其中之一就是免疫检查点抑制/封锁。免疫检验点抗体是通过抑制病人T细胞上的关键免疫检查点蛋白来激活自身免疫系统中的T细胞,从而消灭肿瘤细胞。所以,免疫检验点抗体就相当于将T细胞的“闸门”给打开了。免疫检验点抗体是当前国际单克隆抗体药物研发的大热门。靶向免疫检验点抗体的靶点目前已有报道的至少有7个,即:

ASCO 2015:各种常见和罕见癌症治疗的改善

芝加哥——美国临床肿瘤学会年会(ASCO)第51届年会上今天发布的五个最新研究的结果为常见和罕见的癌症提供了重要的新治疗手段。它们针对包括每年超过50万名美国人共同诊断的黑色素瘤、前列腺癌和乳腺癌患者新的或精致的治疗方法。另一项研究揭示了针对某些特定形式恶性肿瘤的期待已久的新治疗方法。这些软组织肿瘤占每年所有诊断癌症的1%或更少。“这些研究的多样性表明当今癌症研究的活力。我们正在学习更聪明的方式使

“自切肿瘤”为什么会出现两种不同说法?

6月23日,衢州晚报刊登了《绝症男为求生多次自切肿瘤》一文,引起社会关注。这个新闻称,浙江衢州市一位41岁的男子,因患有右上颌骨骨肉瘤,自己买来手术工具,在家中卫生间里,给自己切除口腔右侧新长出的肿瘤。由于肿瘤反复长出,该男子从5月20日开始已经十几次这样为自己“动手术”了。这个新闻发布后,有媒体重新采访后刊发,并被全国不少网络媒体转载,一些媒体将新闻标题改为“生活拮据看病难”。也有一些媒体发表了

Nature:突变p53基因可能改善肿瘤患者的生存期

背景:p53上的错义突变产生异常的蛋白质而废除肿瘤抑制功能,这可以得到致瘤的功能获得性活性,进而促进恶性肿瘤进展、入侵、转移和化学耐药。特别是在肿瘤组织中,突变p53(mutp53)蛋白经历大规模的变构稳定性,这是得到功能获得性活性的关键要素。尽管目前全球有约1100万名的肿瘤患者表达高度稳定突变的p53,但是目前突变p53在体内是否是治疗的靶标依然是未知的。方法:这里我们使用新型的突变p53小鼠

大型前瞻性乳腺肿瘤多中心研究中国站(BE3研究)中期总结即将发布

超声E-成像,全称为二维实时剪切波弹性成像,是法国声科影像创造的全球唯一全面通过FDA认证的实时、全幅、全定量的软组织硬度测量工具,在它出现的短短数年间,其可以在浅表组织、腹部组织、腔内组织广泛便捷应用的特性,得到了国内外顶级超声及医学专家的一致认可。日前,有关E-成像的超大型前瞻性乳腺肿瘤多中心研究中国站(BE3研究)的中期报告即将发布。 2014年6月,BE3研究在西安正式启动,两位PI正是

Baidu
map
Baidu
map
Baidu
map